Home Stocks NVO Novo Nordisk A/S (NYSE: NVO) Healthcare · Drug Manufacturers - General
— —
Quote unavailable · Price data is temporarily unavailable.
The Quantellect read. Short interest is 1.21% of float with a 0.28% borrow fee. Descriptive summary of the data on this page, not a recommendation.
Momentum Neutral RSI (14) 55.9 (overbought above 70, oversold below 30)
Short interest 1.2% of float FINRA settlement Oct 30, 2026
NVO price chart Price — · As of —
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open —
Previous close —
Day range —
52-week range $34.77 – $61.72 Through Nov 18, 2026
Volume —
Average volume (30 calendar days, 0 sessions) — Through Nov 18, 2026
Market cap $176.43B
P/E (TTM) 10.3
Forward P/E 12.1
EPS (TTM) stale vendor snapshot —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) —
Price history NVO · NYSE · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
Quantellect signals Change since Nov 18 Insufficient data · Observed Nov 13, 2026, 6:33 PM ET
Social Pulse 30 mentions in 24h
How the scores work → Industry comparison — · Industry comparison not available
Upcoming events — · Upcoming events not available
Analyst consensus — · Analyst consensus not available
Earnings history — · Earnings history not available
News and press releases Year All 2026 2025 Nov 9, 2026, 4:00 PM ET Nov 2, 2026, 4:05 PM ET Oct 27, 2026, 4:05 PM ET Jul 29, 2026, 4:05 PM ET Jul 22, 2026, 5:15 PM ET Jul 21, 2026, 4:00 PM ET All NVO news → Company profile Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The
CEO —
Headquarters Bagsvaerd, Denmark
Employees 66,700
IPO date Jan 4, 1982
Sector Healthcare
Industry Drug Manufacturers - General Q Score — · Q Score not available
Quantellect signals Change since Nov 18 Insufficient data · Observed Nov 13, 2026, 6:33 PM ET
Social Pulse 30 mentions in 24h
How the scores work → Upcoming events — · Upcoming events not available
Analyst consensus — · Analyst consensus not available
Earnings history — · Earnings history not available
Company profile Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The
CEO —
Headquarters Bagsvaerd, Denmark
Employees 66,700
IPO date Jan 4, 1982
Sector Healthcare
Industry Drug Manufacturers - General